We keep selective experience in pharma when the technical challenges resemble those of banking and insurance.
Current focus
The pharmaceutical sector demands precision, compute-intensive processing and regulatory traceability (GxP). We have selective experience in distributed processing and modernization of internal tools in pharma environments, but our main focus today is banking and insurance, where we have over fifteen years of critical projects.
If your organization is in pharma and faces a similar technical challenge —HPC for simulations, legacy platform modernization or pipeline automation— let’s talk. We assess the fit case by case before committing.
In-silico trials, pharmacokinetics and the analysis of large experimental datasets need the same grid engineering as risk calculation in banking: queues, scheduling, on-demand scaling and monitoring. We apply that know-how to simulation clusters with traceability of every run.
Inherited laboratory and production applications (old databases and forms, undocumented logic) that must evolve without breaking validation. We work in phases, with functional validation at every release, as in the modernisation of actuarial and banking cores.
Automation of data flows with a record of who ran what, when and with which version: the same auditability principles (GitOps, observability, access control) that financial regulation demands.
Our main focus is banking and insurance. In pharma we have selective experience and assess each project case by case, only when the technical challenge resembles the ones we solve every day: HPC, legacy modernisation and automation.
We know the approach of traceability, change control and documentary evidence, which matches what we apply under DORA, Solvency II or ISO 27001. The regulatory validation specific to each system is defined together with the client's quality team.
With a short technical assessment: inventory of the environment, bottlenecks and a phased proposal. If the fit is not right, we say so.
